European Obesity Market To Liven Up After CHMP Backs Saxenda
This article was originally published in The Pink Sheet Daily
Executive Summary
Two new antibiotics, Sivextro and Orbactiv, and a rapidly reversible platelet aggregation inhibitor Kengrexal were also among new drugs backed by Europe’s top advisory panel after CHMP’s first meeting of 2015.
You may also be interested in...
A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years
Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.